These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

583 related items for PubMed ID: 11297606

  • 1. Regional variations of insulin-like growth factor I (IGF-I), IGF-II, and receptor type I in benign prostatic hyperplasia tissue and their correlation with intraprostatic androgens.
    Monti S, Di Silverio F, Iraci R, Martini C, Lanzara S, Falasca P, Poggi M, Stigliano A, Sciarra F, Toscano V.
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1700-6. PubMed ID: 11297606
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Androgen concentrations and their receptors in the periurethral region are higher than those of the subcapsular zone in benign prostatic hyperplasia (BPH).
    Monti S, Di Silverio F, Toscano V, Martini C, Lanzara S, Varasano PA, Sciarra F.
    J Androl; 1998 Apr; 19(4):428-33. PubMed ID: 9733145
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. DHT and testosterone, but not DHEA or E2, differentially modulate IGF-I, IGFBP-2, and IGFBP-3 in human prostatic stromal cells.
    Le H, Arnold JT, McFann KK, Blackman MR.
    Am J Physiol Endocrinol Metab; 2006 May; 290(5):E952-60. PubMed ID: 16368782
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Secretion of insulin-like growth factors and their binding proteins by human normal and hyperplastic prostatic cells in primary culture.
    Boudon C, Rodier G, Lechevallier E, Mottet N, Barenton B, Sultan C.
    J Clin Endocrinol Metab; 1996 Feb; 81(2):612-7. PubMed ID: 8636277
    [Abstract] [Full Text] [Related]

  • 9. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia.
    Di Silverio F, Monti S, Sciarra A, Varasano PA, Martini C, Lanzara S, D'Eramo G, Di Nicola S, Toscano V.
    Prostate; 1998 Oct 01; 37(2):77-83. PubMed ID: 9759701
    [Abstract] [Full Text] [Related]

  • 10. Regional distribution of epidermal growth factor, testosterone and dihydrotestosterone in benign prostatic hyperplasia tissue.
    Sciarra F, Monti S, Adamo MV, Palma E, Toscano V, d'Eramo G, di Silverio F.
    Urol Res; 1995 Oct 01; 23(6):387-90. PubMed ID: 8788277
    [Abstract] [Full Text] [Related]

  • 11. Subnormal tissue 3 alpha-androstanediol and androsterone in prostatic hyperplasia.
    Meikle AW, Stringham JD, Olsen DC.
    J Clin Endocrinol Metab; 1978 Oct 01; 47(4):909-13. PubMed ID: 95628
    [Abstract] [Full Text] [Related]

  • 12. Androgens and estrogens: their interaction with stroma and epithelium of human benign prostatic hyperplasia and normal prostate.
    Krieg M, Bartsch W, Thomsen M, Voigt KD.
    J Steroid Biochem; 1983 Jul 01; 19(1A):155-61. PubMed ID: 6193338
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Insulin-like growth factor-I (IGF-I) and its binding protein IGFBP-4 in human prostatic hyperplastic tissue: gene expression and its cellular localization.
    Barni T, Vannelli BG, Sadri R, Pupilli C, Ghiandi P, Rizzo M, Selli C, Serio M, Fiorelli G.
    J Clin Endocrinol Metab; 1994 Mar 01; 78(3):778-83. PubMed ID: 7510307
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: effects on tissue androgen concentration, 5 alpha-reductase activity and androgen receptor content.
    Forti G, Salerno R, Moneti G, Zoppi S, Fiorelli G, Marinoni T, Natali A, Costantini A, Serio M, Martini L.
    J Clin Endocrinol Metab; 1989 Feb 01; 68(2):461-8. PubMed ID: 2465302
    [Abstract] [Full Text] [Related]

  • 17. Relationships between oestradiol-17 beta, testosterone, dihydrotestosterone and 5 alpha-androstane-3 alpha, 27 beta-diol in human benign hypertrophy and carcinoma of the prostate.
    Ghanadian R, Puah CM.
    J Endocrinol; 1981 Feb 01; 88(2):255-62. PubMed ID: 6162906
    [Abstract] [Full Text] [Related]

  • 18. Effect of epristeride on the expression of IGF-1 and TGF-beta receptors in androgen-induced castrated rat prostate.
    Wu SF, Sun HZ, Qi XD, Tu ZH.
    Exp Biol Med (Maywood); 2001 Nov 01; 226(10):954-60. PubMed ID: 11682703
    [Abstract] [Full Text] [Related]

  • 19. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
    Arnold JT, Le H, McFann KK, Blackman MR.
    Am J Physiol Endocrinol Metab; 2005 Mar 01; 288(3):E573-84. PubMed ID: 15536203
    [Abstract] [Full Text] [Related]

  • 20. Insulin-like growth factor (IGF)-I, IGF-II and IGF type I receptor (IGFR-I) expression in prostatic cancer.
    Cardillo MR, Monti S, Di Silverio F, Gentile V, Sciarra F, Toscano V.
    Anticancer Res; 2003 Mar 01; 23(5A):3825-35. PubMed ID: 14666684
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.